Year 2023 / Volume 115 / Number 6
Letter
Use of teduglutide for short bowel syndrome and Crohn’s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy

331-332

DOI: 10.17235/reed.2022.9194/2022

Lidia Martí Romero, Laura Peño Muñoz, Vanesa Martínez Escapa, Joaquín Hinojosa del Val,

Abstract
Surgery in Crohn’s disease may be the cause of short bowel syndrome that may lead to kidney dysfunction. Dual biologic therapy is rarely needed to control activity. We present a case of a 61-year-old steroid dependent (A2L1B3p) female who had undergone surgery on three occasions: ileocecal resection (resection of 15 cm of terminal ileum); resection of right and left colon up to sigmoid; proctectomy with intersphincteric resection along with ileostomy due to a rectovaginal fistula. She had been previously treated with prednisone, azathioprine, methotrexate, infliximab and adalimumab but the treatment was discontinued owing to adverse effects. Vedolizumab was started, showing good control of the luminal activity but the rectovaginal fistula recurred. Treatment changed to ustekinumab, the fistula activity was controlled but the mucosa activity recurred. 11 months after commencing with ustekinumab, vedolizumab was added to the treatment and complete remission was achieved for three years. Simultaneously, the patient developed renal dysfunction derived from the short bowel syndrome that led to chronic kidney failure. In the face of potential renal replacement therapy, a new therapy with 2.5 mg/sc/d teduglutide was started achieving stable figures of creatinine and normalization of the glomerular filtration rate.
Share Button
New comment
Comments
No comments for this article
References
1- Pironi L, Arends J, Baxter J, et al. Home Artificial Nutrition & Chronic Intestinal Failure; Acute Intestinal Failure Special Interest Groups of ESPEN. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015;34(2):171-80.
2- López F., Martínez P., Lal S. Chronic intestinal failure: an overview and future perspectives. Rev Esp Enferm Dig 2022:114(5):251-253. Doi: 10.17235/reed.2022.8827/2022
3 - Kochar B, Long M.D, Shelton E, et al. Safety and Efficacy of Teduglutide (Gattex) in patients with Crohn’s disease and need for parenteral support due to short bowel syndrome associated intestinal failure. J Clin Gastroenterol. 2017 July ; 51(6): 508–511. doi: 10.1097/MCG.0000000000000604
4 - Mao EJ., Lewin S., Terdiman JP., et al. Safety of dual biological therapy in Crohn’s disease: a case series of vedolizumab in combination with other biologics. BMJ Open Gastro 2018;5:e000243. Doi:10.1136/bmjgast-2018-000243
5 - Liu E.Y., Loomes D.E. Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn’s disease. Case Rep Med 2017;2017: 5264216.
Related articles

Letter

Duodenal stenosis surgical treatment in Crohn’s disease

DOI: 10.17235/reed.2023.9521/2023

Digestive Diseases Image

Peristomal cutaneous Crohn's disease by contiguity

DOI: 10.17235/reed.2022.8909/2022

Letter

Encephalopathy in short bowel syndrome: a diagnostic challenge

DOI: 10.17235/reed.2022.8826/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Review

Intestinal failure in adults and children

DOI: 10.17235/reed.2020.6981/2020

Letter

Crohn’s disease in patients treated with etanercept

DOI: 10.17235/reed.2019.6554/2019

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Letter to the Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Case Report

Metastatic Crohn’s disease in pediatrics

DOI: 10.17235/reed.2016.3948/2015

Letter to the Editor

Crohn’s disease and Sweet’s syndrome: A debut together

DOI: 10.17235/reed.2015.3842/2015

Case Report

Ovarian involvement in Crohn´s disease: A rare complication

DOI: 10.17235/reed.2015.3764/2015

Citation tools
Martí Romero L, Peño Muñoz L, Martínez Escapa V, Hinojosa del Val J. Use of teduglutide for short bowel syndrome and Crohn’s disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy. 9194/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 675 visits.
This article has been downloaded 111 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 08/09/2022

Accepted: 21/09/2022

Online First: 30/09/2022

Published: 06/06/2023

Article Online First time: 22 days

Article editing time: 271 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology